Secular trends in opioid prescribing in the USA

Journal of Pain Research

Volumn 10, Issue , 2017, Pages 383-387

  Pezalla, Edmund J ^a   Rosen, David ^b   Erensen, Jennifer G ^b   Haddox, J David ^b,c   Mayne, Tracy J ^b  

^a Bioconsult LLC   (United States)

^b PURDUE PHARMA L P   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Legislation; OADP; Opioids; Prescription; Utilization trends

Indexed keywords

BUPRENORPHINE; HYDROCODONE BITARTRATE; MORPHINE SULFATE PLUS NALTREXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYCODONE PLUS PARACETAMOL; TAPENTADOL; TRAMADOL;

ABUSE DETERRANT FORMULATION; ARTICLE; DRUG ABUSE; DRUG UTILIZATION; HUMAN; PRESCRIPTION; PUBLIC POLICY; REIMBURSEMENT; TREND STUDY; UNITED STATES;

EID: 85013225910     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S129553     Document Type: Article

References (18)

1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths — United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.
2. Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration; 2015. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf. Accessed October 28, 2016.
3. FDA guidance on abuse-deterrent opioids — evaluation and labeling. Available from: http://www.fda.gov/RegulatoryInformation/Guidances/default.htm. Accessed October 29, 2016.
4. Warner M, Hedegaard H, Chen LH. Trends in Drug-Poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 1999–2012;2014. Available from: https://www.cdc.gov/nchs/data/hes-tat/drug_poisoning/drug_poisoning_deaths_1999-2012.pdf. Accessed October 29, 2016.
5. Opioid abuse task force. Assembly Committee on Health, AB1977 (Wood)-Amended April 13; 2016. Available from: www.legtrack.com/cache/285312.doc. Accessed November 2, 2016.
6. FDA Facts Abuse-Deterrent Opioid Medications. Available from: http://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm514939.htm. Accessed November 2, 2016.
7. DEA Reduces amount of opioid controlled substances to be manufactured in 2017. Available from: https://www.dea.gov/divisions/hq/2016/hq100416.shtml. Accessed October 29, 2016.
8. Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007–2012. Am J Prev Med. 2015;49(3):409–413.
9. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–248.
10. Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiat. 2015;72(5):424–429.
11. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes – Florida, 2010–2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):569–574.
12. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–163.
13. Centers for Disease Control and Prevention. Influx of Fentanyl-Laced Counterfeit Pills and Toxic Fentanyl-Related Compounds Further Increases Risk of Fentanyl-Related Overdose and Fatalities. HAN Health Advisory; 2016. Available from: http://health.mo.gov/emergencies/ert/alertsadvisories/pdf/cdc-update82616.pdf. Accessed October 29, 2016.
14. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155–1160.
15. Haffajee RL, Jena AB, Weiner SG. Mandatory use of prescription drug monitoring programs. JAMA. 2015;313(9):891–892.
16. NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain; 2014. Bethesda, MD. Available from: https://prevention.nih.gov/docs/programs/p2p/OpioidPainTreatmnt_Program-Book.pdf. Accessed November 2, 2016.
17. Volkow ND, McLellan AT. Opioid abuse in chronic pain – misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–1263.
18. State Naloxone and Good Samaritan Legislation, December, 2015. Available from: https://www.whitehouse.gov/sites/default/files/ondcp/Blog/naloxonecirclechart_january2016.pdf. Accessed October 16, 2016.